An investigator-initiated clinical trial will assess the safety and efficacy of NKX019, Nkarta’s investigational natural killer (NK) cell therapy for autoimmune diseases, in people with myasthenia gravis (MG). The open-label Phase 1 trial will be led by researchers at the University of California, Irvine, and the University…
The presence of antibodies targeting titin, a type of muscle protein, in patients with myasthenia gravis (MG) not associated with a thymus tumor is related to more frequent hospitalizations, according to a study in China. Frequent hospitalizations hurt quality of life and mental health for people with MG, and…
Treatment with Vyvgart (efgartigimod) may rapidly and safely ease symptoms during an impending myasthenic crisis in people with myasthenia gravis (MG), according to a study in China. Impending myasthenic crisis, or IMC, refers to symptoms rapidly worsening within a short time that may lead to a myasthenic crisis,…
A maintenance regimen using an intravenous immunoglobulin (IVIG) therapy may reduce disease severity and improve function in people with generalized myasthenia gravis, according to data from a Phase 2 clinical trial. IVIG is commonly used to treat acute symptom worsening in people with myasthenia gravis (MG). The …
The European Medicines Agency granted orphan drug status to the experimental cell therapy KYV-101 to treat myasthenia gravis (MG). The designation is given to medicines that aim to treat life-threatening or chronic debilitating conditions affecting no more than five in every 10,000 people. It provides companies with several…
Soliris (eculizumab) effectively eased disease severity and reduced the need for immunosuppressive therapies in people with treatment-resistant generalized myasthenia gravis with anti-AChR antibodies, a real-world study in Italy shows. The treatment also reduced the number of disease exacerbations that required rescue therapy, such as intravenous immunoglobulin (IVIG)…
Myasthenia gravis (MG) patients who are women or have a tumor in the thymus gland are more likely to require intensive care due to disease exacerbation, a retrospective study in Finland suggests. Patients with late-onset disease in whom disease symptoms become apparent after the age of 50 were also…
The new UCB Myasthenia Gravis Scholarship, launched by the Belgium-based biopharmaceutical company, is aiming to help myasthenia gravis (MG) patients and their family members in the U.S. to continue their education or learn new skills by covering educational expenses — with program awards totaling up to $150,000. “We…
Myasthenia gravis (MG) cases increased gradually from 2000 to 2020 in Denmark, Finland, and Sweden, with the total number of cases and the number of newly diagnosed cases both rising, according to a population-based study. The number of newly diagnosed cases was higher among men older than 50 and…
The case of a 72-year-old man who developed myasthenia gravis (MG) and myocarditis, or inflammation of the heart, following chemoimmunotherapy for gastric cancer that included sintilimab showcases the need to better understand how this treatment can induce the immune disorder, said researchers in China. Sintilimab is a type of…
Get regular updates to your inbox.
